BDBM494877 US10994015, Example 11

SMILES Clc1ccccc1CNc1ncnc2[nH]c(cc12)-c1ccc(CCOCCNc2cccc3C(=O)N(C4CCC(=O)NC4=O)C(=O)c23)cc1

InChI Key InChIKey=GONZJBXMEAMLKR-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 494877   

TargetEpidermal growth factor receptor(Human)
Arvinas Operations

US Patent
LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50: 8.40nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50: 0.140nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50: 1.70E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Arvinas Operations

US Patent
LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50: 49nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Arvinas Operations

US Patent
LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50: 0.400nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Arvinas Operations

US Patent
LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50: 3.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Arvinas Operations

US Patent
LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50: 3.50E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Arvinas Operations

US Patent
LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50: 190nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent